Andrea Rosario Beccari
Andrea Rosario Beccari
Head EXSCALATE Platform, Dompe Farmaceutici SpA
Verified email at
Cited by
Cited by
ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets
C Bizzarri, AR Beccari, R Bertini, MR Cavicchia, S Giorgini, M Allegretti
Pharmacology & therapeutics 112 (1), 139-149, 2006
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
S Günther, PYA Reinke, Y Fernández-García, J Lieske, TJ Lane, HM Ginn, ...
Science 372 (6542), 642-646, 2021
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2
A Moriconi, MC Cesta, MN Cervellera, A Aramini, S Coniglio, S Colagioia, ...
Journal of medicinal chemistry 50 (17), 3984-4002, 2007
Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities
R Cannalire, C Cerchia, AR Beccari, FS Di Leva, V Summa
Journal of medicinal chemistry 65 (4), 2716-2746, 2020
Targeting C5a: recent advances in drug discovery
M Allegretti, A Moriconi, AR Beccari, RD Bitondo, C Bizzarri, R Bertini, ...
Current medicinal chemistry 12 (2), 217-236, 2005
Combining molecular modeling with experimental methodologies: mechanism of membrane permeation and accumulation of ofloxacin
M Fresta, S Guccione, AR Beccari, PM Furneri, G Puglisi
Bioorganic & medicinal chemistry 10 (12), 3871-3889, 2002
PARP1-produced poly-ADP-ribose causes the PARP12 translocation to stress granules and impairment of Golgi complex functions
G Catara, G Grimaldi, L Schembri, D Spano, G Turacchio, M Lo Monte, ...
Scientific reports 7 (1), 1-17, 2017
Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor
R Bertini, LS Barcelos, AR Beccari, B Cavalieri, A Moriconi, C Bizzarri, ...
British journal of pharmacology 165 (2), 436-454, 2012
SARS-CoV-2 entry inhibitors: Small molecules and peptides targeting virus or host cells
R Cannalire, I Stefanelli, C Cerchia, AR Beccari, S Pelliccia, V Summa
International journal of molecular sciences 21 (16), 5707, 2020
Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief
A Moriconi, TM Cunha, GR Souza, AH Lopes, FQ Cunha, VL Carneiro, ...
Proceedings of the National Academy of Sciences 111 (47), 16937-16942, 2014
LiGen: a high performance workflow for chemistry driven de novo design
AR Beccari, C Cavazzoni, C Beato, G Costantino
Journal of chemical information and modeling 53 (6), 1518-1527, 2013
Identification of inhibitors of SARS-CoV-2 3CL-pro enzymatic activity using a small molecule in vitro repurposing screen
M Kuzikov, E Costanzi, J Reinshagen, F Esposito, L Vangeel, M Wolf, ...
ACS pharmacology & translational science 4 (3), 1096-1110, 2021
Computational studies of SARS-CoV-2 3CLpro: Insights from MD simulations
A Grottesi, N Bešker, A Emerson, C Manelfi, AR Beccari, F Frigerio, ...
International journal of molecular sciences 21 (15), 5346, 2020
Auto-regulation of secretory flux by sensing and responding to the folded cargo protein load in the endoplasmic reticulum
A Subramanian, A Capalbo, NR Iyengar, R Rizzo, A di Campli, ...
Cell 176 (6), 1461-1476. e23, 2019
The ANTAREX approach to autotuning and adaptivity for energy efficient HPC systems
C Silvano, G Agosta, S Cherubin, D Gadioli, G Palermo, A Bartolini, ...
Proceedings of the ACM International Conference on Computing Frontiers, 288-293, 2016
Molecular mechanism and functional role of brefeldin A-mediated ADP-ribosylation of CtBP1/BARS
A Colanzi, G Grimaldi, G Catara, C Valente, C Cericola, P Liberali, ...
Proceedings of the National Academy of Sciences 110 (24), 9794-9799, 2013
Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls
M Allegretti, R Bertini, C Bizzarri, A Beccari, A Mantovani, M Locati
Trends in pharmacological sciences 29 (6), 280-286, 2008
Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring
F Oger, A Lecorgne, E Sala, V Nardese, F Demay, S Chevance, ...
Journal of medicinal chemistry 53 (5), 1937-1950, 2010
Use of experimental design to optimize docking performance: The case of ligendock, the docking module of ligen, a new de novo design program
C Beato, AR Beccari, C Cavazzoni, S Lorenzi, G Costantino
Journal of chemical information and modeling 53 (6), 1503-1517, 2013
A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics
J Gossen, S Albani, A Hanke, BP Joseph, C Bergh, M Kuzikov, E Costanzi, ...
ACS pharmacology & translational science 4 (3), 1079-1095, 2021
The system can't perform the operation now. Try again later.
Articles 1–20